In clinical research in 2020, over 7.6 years of monitoring and follow-up reported that the change of the annual mean EGFR in type 1 diabetes was −5.7 and in healthy people, it was 0.6 mL/min/1.73 m2, which demonstrates the potential rapid biomarker and possible therapeutic targets for individuals with type 2 diabetes [61]. The gene discussed is EGFR; the disease is type 1 diabetes mellitus.